Retinal Pharmacotherapy

By

  • Quan Nguyen, MD. MSc MD, MSc, McGaw Memorial Endowed Chair in Ophthalmology; Professor and Chairman; Inaugural Director of the Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center,Omaha, Nebraska, US
  • Eduardo Rodrigues, MD, Professor de Oftalmologia do Departamento de Oftalmologia e Ciências Visuais da UNIFESP/EPM
  • Michel Farah, MD MD, Mestrado, Doutorado e Livre-docência em Oftalmologia pela Universidade Federal de São Paulo (UNIFESP/EPM) Professor associado, orientador da Pós-graduação da UNIFESP/EPM
  • William F Mieler, MD, Cless Family Professor and Vice-Chairman, Director Residency and Vitreoretinal Fellowship Training, Department of Ophthalmology & Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA

Retinal Pharmacotherapy is the first comprehensive book devoted to pharmacologic agents and their rationale and mechanisms of action in selected retinal and uveitic diseases. Drs. Quan Dong Nguyen, Eduardo Buchele Rodrigues, Michel Eid Farah, and William F. Mieler lead an international team of expert contributors to present up-to-date knowledge of new drugs on the market, the science behind the drugs, evidence of how the drugs work, and the reasons why they are effective or not. This user-friendly, all-in-one reference provides you with easy access to practical information on the effective and appropriate use of pharmacologic agents in the management of retinal diseases.
View full description

Audience

Opthalmology, Optometrist

 

Book information

  • Published: February 2010
  • Imprint: SAUNDERS
  • ISBN: 978-1-4377-0603-1


Table of Contents

1 Evolving Knowledge in Pharmacologic
Treatments

Section 1: Basic Sciences in Retina

2 Retinal Anatomy and Pathology

3 Retinal Biochemistry, Physiology and
Cell Biology

4 Ocular Angiogenesis: Vascular Endothelial
Growth Factor and Other Factors

5 Ocular Immunity and Inflammation

6 Complement Activation and Inhibition in
Retinal Disease

7 Genetics of Retinal Disease

Section 2: Animal Models and Routes for
Retinal Drug Delivery

8 Vitamins and Supplements for Age-Related
Macular Degeneration

9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems

0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy

11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal
Gas-Phase Nanoparticles

12 Routes for Drug Delivery: Sustained-Release
Devices

13 Microspheres and Nanotechnology for
Drug Delivery

14 Thermo-sensitive Hydrogels

15 Retina and Ocular Toxicity to Ocular Application
of Drugs

16 Retinal Toxicity of Systemic and Topical
Medications

Section 3: Retinal Diseases Amenable to Pharmacotherapy

17 Non-neovascular Age-Related Macular
Degeneration

18 Neovascular Age-Related Macular Degeneration

19 Diabetic Retinopathy and Diabetic
Macular Edema

20 Retinal Vein Occlusion

21 Retinal Detachment and Proliferative
Vitreoretinopathy

22 Posterior Uveitis

23 Choroidal Neovascularization Secondary
to Inflammation, Infection, and Myopia

24 Ocular Infection: Endophthalmitis

25 Retinopathy of Prematurity

26 Idiopathic Macular Telangiectasia

27 Neovascular Glaucoma

28 Retinal Hereditary and Degenerative /
Dystrophic Diseases (non-AMD)

Section 4: Drugs and Mechanisms in
Retinal Diseases

29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
in the Treatment of Retinal Diseases

30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others

31 Anecortave Acetate

32 Therapeutic Monoclonal Antibodies and
Fragments: Bevacizumab

33 Therapeutic Monoclonal Antibodies and
Fragments: Ranibizumab

34 Pathophysiology of Vascular Endothelial Growth
Factor and Other Angiogenic Molecules

35 Biologic Therapies: Infliximab, Adalimumab,
Etanercept, Daclizumab, and Others

36 Immunomodulatory Therapy in Uveitis

37 Fusion Proteins: VEGF-Trap

38 Aptamers and Intramers: Pegaptanib

39 Protein Kinase C Inhibitor: Ruboxistaurin

40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP

41 Ocular Gene Therapy

42 Neuroprotection and Retinal Diseases

43 Photosensitizers and Photodynamic Therapy:
Verteporfin

44 Chemotherapy for Malignant Intraocular Tumors

45 Antibiotics

Section 5: Pharmacotherapy and Surgery

46 Rheotherapy (Rheopheresis; Therapeutical
Apheresis)

47 Enzymatic Vitrectomy and Pharmacologic
Vitreodynamics

48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy

49 Epimacular and External Radiotherapy

50 Current Status of Human Retinal Pigment
Epithelial Transplantation

Section 6: The Last Words

51 Off-Label Drugs and the Impact of the Food and
Drug Administration in the Treatment of
Retinal Disease

52 Value-Based Medicine and Pharmacoeconomics

53 Future Perspectives: Agents on the Horizon